Neutralizing antibodies directed against the V3 loop select for different escape variants in a virus with mutated reverse transcriptase (M184V) than in wild-type human immunodeficiency virus type 1
- PMID: 9643373
- DOI: 10.1089/aid.1998.14.735
Neutralizing antibodies directed against the V3 loop select for different escape variants in a virus with mutated reverse transcriptase (M184V) than in wild-type human immunodeficiency virus type 1
Abstract
The M184V substitution in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) encodes high-level resistance to the (-)-enantiomer of 2',3'-dideoxy-3'-thiacytidine (3TC) and low-level resistance to each of 2',3'-dideoxycytidine (ddC) and 2',3'-dideoxyinosine (ddI). This mutation also results in decreased HIV replication fitness in primary cells, diminished RT processivity, and increased RT fidelity. To assess the effect of this substitution on genetic variation in the HIV env region, we cultured both M184V-containing and wild-type BH10 in MT-4 cells in the presence of the neutralizing monoclonal antibody 447-52D, targeted to the GPGR epitope within the V3 loop of gp120. Outgrowth of viruses resistant to neutralization was followed by sequence analysis of the V3 loop by standard methodology. Wild-type HIV first showed escape after 15-22 days in culture. Sequence analysis revealed an arginine-to-lysine change within the GPGR epitope in the V3 loop (R20K, AGA --> AAA) in six of six clones sequenced after day 36. In contrast, M184V-containing HIV first showed escape between days 25 and 32 and sequence analysis revealed an aspartate-to-tyrosine change at amino acid 5 in V3 (N5Y; AAC --> TAC) in two of six clones at day 36 and in five of five clones at day 55. Similar results were obtained in two independent antibody selection protocols. The escape mutation in the wild type is consistent with the G --> A hypermutation observed in wild-type HIV-1, recently shown to cause an initial M184I change (before M184V) in 3TC-treated patients. In contrast, the N5Y substitution seen with M184V-containing HIV-1 is an A --> T transversion in V3.
Similar articles
-
Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.J Virol. 2007 Apr;81(8):3757-68. doi: 10.1128/JVI.01544-06. Epub 2007 Jan 24. J Virol. 2007. PMID: 17251298 Free PMC article.
-
The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.AIDS Res Hum Retroviruses. 2004 Nov;20(11):1254-8. doi: 10.1089/aid.2004.20.1254. AIDS Res Hum Retroviruses. 2004. PMID: 15588347
-
Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1.J Gen Virol. 1996 Apr;77 ( Pt 4):753-8. doi: 10.1099/0022-1317-77-4-753. J Gen Virol. 1996. PMID: 8627264
-
HIV-1 neutralization directed to epitopes other than linear V3 determinants.AIDS. 1991;5 Suppl 2:S135-43. doi: 10.1097/00002030-199101001-00019. AIDS. 1991. PMID: 1726953 Review. No abstract available.
-
[Sequence variation of HIV and bioinformatics].Uirusu. 2004 Jun;54(1):33-8. doi: 10.2222/jsv.54.33. Uirusu. 2004. PMID: 15449902 Review. Japanese.
Cited by
-
The M184V mutation in reverse transcriptase can delay reversion of attenuated variants of simian immunodeficiency virus.J Virol. 2002 Sep;76(17):8958-62. doi: 10.1128/jvi.76.17.8958-8962.2002. J Virol. 2002. PMID: 12163615 Free PMC article.
-
Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.Antimicrob Agents Chemother. 2003 Nov;47(11):3377-83. doi: 10.1128/AAC.47.11.3377-3383.2003. Antimicrob Agents Chemother. 2003. PMID: 14576091 Free PMC article. Review. No abstract available.
-
Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins.PLoS One. 2013;8(3):e59803. doi: 10.1371/journal.pone.0059803. Epub 2013 Mar 22. PLoS One. 2013. PMID: 23533650 Free PMC article.
-
Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters.BMC Immunol. 2006 Oct 31;7:25. doi: 10.1186/1471-2172-7-25. BMC Immunol. 2006. PMID: 17076905 Free PMC article.
-
Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1.Clin Diagn Lab Immunol. 2003 Nov;10(6):979-81. doi: 10.1128/cdli.10.6.979-981.2003. Clin Diagn Lab Immunol. 2003. PMID: 14607855 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous